GSK outlines plans for dual-acting COPD drug after positive Phase II data
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has unveiled positive Phase II data on GSK961081, a dual-acting muscarinic antagonist and ß2-agonist (MABA), showing that the drug improved lung function in patients with chronic obstructive pulmonary disease (COPD).